Analysts’ Opinions Are Mixed on These Healthcare Stocks: Teleflex (TFX) and Biogen (BIIB)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Teleflex (TFX – Research Report) and Biogen (BIIB – Research Report).
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Teleflex (TFX)
RBC Capital analyst Shagun Singh Chadha maintained a Hold rating on Teleflex on January 20 and set a price target of $115.00. The company’s shares closed last Wednesday at $102.96.
According to TipRanks.com, Chadha is a 3-star analyst with an average return of
Currently, the analyst consensus on Teleflex is a Hold with an average price target of $133.20, representing a 31.6% upside. In a report issued on January 8, TipRanks – xAI also reiterated a Hold rating on the stock with a $132.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Biogen (BIIB)
In a report issued on January 20, Brian Abrahams from RBC Capital maintained a Buy rating on Biogen, with a price target of $217.00. The company’s shares closed last Wednesday at $172.62.
According to TipRanks.com, Abrahams is a 4-star analyst with an average return of
Biogen has an analyst consensus of Moderate Buy, with a price target consensus of $190.11, which is a 15.0% upside from current levels. In a report issued on January 7, Mizuho Securities also maintained a Buy rating on the stock with a $207.00 price target.
